AGEN - Agenus Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.5400
+0.0100 (+0.40%)
At close: 4:00PM EDT

2.5400 0.00 (0.00%)
After hours: 4:39PM EDT

Stock chart is not supported by your current browser
Previous Close2.5300
Open2.5700
Bid2.5400 x 4000
Ask2.5500 x 1100
Day's Range2.4700 - 2.5800
52 Week Range1.5400 - 3.8800
Volume795,423
Avg. Volume1,352,159
Market Cap340.881M
Beta (3Y Monthly)2.09
PE Ratio (TTM)N/A
EPS (TTM)-1.4430
Earnings DateJul 28, 2017 - Jul 31, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
Trade prices are not sourced from all markets
  • Why Is Agenus (AGEN) Down 13% Since Last Earnings Report?
    Zacks10 days ago

    Why Is Agenus (AGEN) Down 13% Since Last Earnings Report?

    Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Gilead Files sNDA for Label Expansion of HIV Therapy Descovy
    Zacks14 days ago

    Gilead Files sNDA for Label Expansion of HIV Therapy Descovy

    Gilead (GILD) submits sNDA to the FDA for label expansion of Descovy as PrEP to reduce the risk of sexually acquired HIV-1 infection.

  • PR Newswire21 days ago

    Agenus Begins Dosing with Next-Gen Anti-CTLA-4 Antibody

    LEXINGTON, Mass., April 2, 2019 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a pipeline of immune-modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, today announced that the first patient was dosed in the clinical trial of its next-generation anti-CTLA-4 antibody (AGEN1181). AGEN1181, a novel 'Fc engineered' antibody with potential for enhanced anti-tumor functions, is specifically designed to boost cancer killing immune cells and deplete cells that block the activity of these cancer killing cells. The first patient in the trial was dosed by Dr. Steven J. O'Day, M.D., Executive Director of the John Wayne Cancer Institute & Cancer Clinic, and a pioneer in delivering immune therapies to patients with cancer.  Dr. O'Day's pivotal work has led to the approvals of commercial antibodies targeting CTLA-4 and PD-1.  "AGEN1181 represents an important next-generation breakthrough with its potential for enhanced immune activation and tumor fighting abilities," said Dr. O'Day.

  • PR Newswirelast month

    Agenus Announces Clinical Appointments

    LEXINGTON, Mass., March 21, 2019 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced new leadership appointments as its CTLA-4 and PD-1 programs advance towards a planned BLA filing in 2020. Dr. Manuel Hidalgo, MD, PhD, joins as Strategic Advisor. Dr. Hidalgo, an internationally renowned oncologist, has led clinical development of more than 50 novel anticancer agents including erlotinib, temsirolimus and nab-paclitaxel, which are FDA approved for the treatment of cancer.

  • 3 Top Growth Stocks to Buy Right Now
    Motley Foollast month

    3 Top Growth Stocks to Buy Right Now

    Surprise! This retailer and lesser-known biotechnology company could be potential multibaggers.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of AGEN earnings conference call or presentation 14-Mar-19 12:30pm GMT

    Q4 2018 Agenus Inc Earnings Call

  • Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up
    Zackslast month

    Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up

    Agenus (AGEN) gets a $7.5-million milestone payment from Gilead following the FDA acceptance of the company's IND filing for AGEN1423. Shares rise.

  • Agenus Inc (AGEN) Q4 2018 Earnings Conference Call Transcript
    Motley Foollast month

    Agenus Inc (AGEN) Q4 2018 Earnings Conference Call Transcript

    AGEN earnings call for the period ending December 31, 2018.

  • Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates
    Zackslast month

    Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates

    Agenus (AGEN) delivered earnings and revenue surprises of -42.86% and -19.63%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Agenus: 4Q Earnings Snapshot

    On a per-share basis, the Lexington, Massachusetts-based company said it had a loss of 40 cents. The biotechnology company posted revenue of $5.4 million in the period. For the year, the company reported ...

  • PR Newswirelast month

    Agenus Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

    - Gilead collaboration results in cash infusion of $150M ; first milestone payment of $7.5M triggered - CTLA-4 & PD-1 trials are accruing for planned BLA filing as early as 2020 - Next-Gen CTLA-4 advancing ...

  • PR Newswirelast month

    Agenus Milestone Triggers $7.5M Payment from Gilead

    LEXINGTON, Mass., March 13, 2019 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced today that the FDA has accepted the company's IND filing for AGEN1423 - a milestone in its partnership with Gilead Sciences, Inc. This milestone triggered a cash payment of $7.5M. Agenus is eligible to receive additional milestone payments in 2019 and beyond.

  • Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy
    Zackslast month

    Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy

    Gilead (GILD) presents encouraging data on two leading HIV regimens, Bikatrvy and Descovy.

  • The 3 Oldest Members of Biotech's Billion-Burned Club
    Motley Fool2 months ago

    The 3 Oldest Members of Biotech's Billion-Burned Club

    These biopharmaceutical startups have been losing their investors' money for decades.

  • GlobeNewswire2 months ago

    Analysis: Positioning to Benefit within Micron Technology, Caterpillar, Agenus, Fossil Group, Marathon Petroleum, and Geo Group — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Feb. 20, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.

  • PR Newswire2 months ago

    Agenus Launches First Asset-Backed Digital-Security Offering in Healthcare

    LEXINGTON, Mass., Feb. 19, 2019 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, announced today the launch of its Biotech Electronic Security Token (BEST), the first digital-security offering in healthcare. Agenus will host a conference call and live audio webcast today at 11:00 a.m. ET to discuss the launch of BEST and provide a full briefing on the digital security and offering process. Agenus previously announced that BEST is designed to be an innovative and transformative way to finance drug development by increasing liquidity, minimizing dilution, and improving capital allocation.  BEST is envisioned as a way to democratize financing through targeted investments for specific therapeutic drug products.

  • PR Newswire2 months ago

    Agenus to Host Call to Launch First Asset-Backed Digital-Security Offering in Healthcare on February 19, 2019

    LEXINGTON, Mass., Feb. 15, 2019 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, announced today that its Biotech Electronic Security Token (BEST), the first digital-security offering in healthcare, will be launched on February 19, 2019. In association with the launch, Agenus will host a conference call and live webcast at 11:00 a.m. ET on the same day, to provide a full briefing on the digital security and offering process. Webcast will be also accessible from the "Events & Presentations" section of the Company's investor website at www.agenusbio.com.

  • Why Agenus Inc. Stock Took Flight in January
    Motley Fool2 months ago

    Why Agenus Inc. Stock Took Flight in January

    Agenus' stock crushed it last month. Here's why.

  • Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat
    Zacks2 months ago

    Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat

    A mixed fourth-quarter for biotech bigwig Gilead as it misses on earnings but beat on revenues.

  • Will Gilead (GILD) Q4 Earnings Disappoint on Weak HCV Sales?
    Zacks3 months ago

    Will Gilead (GILD) Q4 Earnings Disappoint on Weak HCV Sales?

    Gilead (GILD) is scheduled to report fourth-quarter results on Feb 4. Investors will likely focus on the strong HIV franchise and other pipeline updates.

  • PR Newswire3 months ago

    Atomic Capital Kicks off Investor Forum Announcing Digital Offering for NASDAQ-Traded Biotech Group, Agenus Inc.

    NEW YORK, Jan. 29, 2019 /PRNewswire/ -- At a gathering of institutional investors this morning, Atomic Capital and Agenus Inc (AGEN), announced the  launch of a groundbreaking digital securities offering enabling the direct participation of accredited investors in Agenus' lead immuno-oncology asset. The proceeds from the digital securities offering, the first conducted by a publicly-traded company, will go to fund product development through FDA approval and commercialization, of the asset, with returns to investors backed by future product sales. "Atomic Capital is deeply committed to leveraging the transformative capabilities of Distributed Ledger Technology in the pursuit of our mission to make capital smarter."  said Alexander S. Blum, CEO of Atomic Capital.

  • PR Newswire3 months ago

    Agenus to Launch the First Asset-Backed Digital Security Offering in Healthcare

    LEXINGTON, Mass., Jan. 29, 2019 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, announced today, the upcoming launch of its Biotech Electronic Security Token (BEST), the first digital security offering in healthcare.  Tokenization will enable qualified investors to directly invest in a single biotech product while preserving shareholder equity. The growing adoption of blockchain technology, together with the latest financial regulatory changes, offers new alternatives to fund selected products with digital securities and opens an unprecedented opportunity to target financial investments in pharmaceutical product development. "Today, by announcing the first of its kind asset backed digital security offering in healthcare, we open the doors for a transformative financing vehicle," said Garo Armen, Chairman and CEO of Agenus.

  • PR Newswire3 months ago

    Agenus Closes $150 Million Immuno-Oncology Transaction with Gilead

    LEXINGTON, Mass., Jan. 24, 2019 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, and adoptive cell therapies1, today announced the closing of its immuno-oncology (I-O) partnership deal with Gilead Sciences, Inc. (GILD), focused on the development and commercialization of up to five novel immuno-oncology therapies. Under the terms of the agreement, Agenus receives $150 million in connection with closing, which includes a $120 million upfront cash payment and a $30 million equity investment.  The agreement also includes approximately $1.7 billion in potential future fees and milestones.  Gilead received worldwide exclusive rights to AGEN1423.

  • GlobeNewswire3 months ago

    Research Report Identifies Conagra Brands, W.R. Grace, International Flavors & Fragrances, Spirit Airlines, Sunstone Hotel Investors, and Agenus with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Jan. 09, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Agenus (AGEN) Surges: Stock Moves 9.4% Higher
    Zacks3 months ago

    Agenus (AGEN) Surges: Stock Moves 9.4% Higher

    Agenus (AGEN) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.